Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting
GlobeNewswire - Mon May 12, 7:01AM CDT
-- Improvements in cognitive performance in animal models are consistent with MDX effects in human adults with ADHD -
Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
GlobeNewswire - Thu May 08, 11:21AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that FDA has approved the protocol for the Company's planned Phase IIb clinical trial of MDX for the treatment of Fragile X Syndrome. The trial is expected to begin enrolling patients shortly.
Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences
GlobeNewswire - Thu May 08, 7:02AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.
Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014
GlobeNewswire - Wed May 07, 3:46PM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter of 2014 and will host a corporate update conference call on Thursday, May 15, 2014.
Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting
GlobeNewswire - Mon May 05, 8:41AM CDT
-- MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo
Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders
GlobeNewswire - Thu May 01, 7:13AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that the United States Patent and Trademark Office ("USPTO"
Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings
GlobeNewswire - Thu Apr 24, 7:01AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, will present new data for Metadoxine Extended Release (MDX or MG01CI) at the upcoming 167 Annual Meeting of the American Psychiatric Association (APA) and 69 Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), both held in New York, NY. Details of the presentations are as follows:
Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
GlobeNewswire - Thu Apr 10, 11:30AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it has submitted a protocol to the FDA for a Phase IIb clinical trial for its MDX product candidate for the treatment of patients with Fragile X Syndrome.
Alcobra Announces Shares Uplisted to NASDAQ Global Market
GlobeNewswire - Wed Mar 26, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that its stock has been approved to list on the Nasdaq Global Market, effective with the open of the stock market on Friday, March 28, 2014. Until the stock is transferred to Nasdaq Global Market, ADHD's stock will continue to trade on the Nasdaq Capital Market. The company will continue to trade under its existing ticker symbol "ADHD."
Pipeline Update from Alcobra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 11:10AM CDT
Alcobra enrolled the first patient in a randomized, placebo-controlled phase III study on metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD).
Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...
Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that, following the recent FDA acceptance of the Company's IND for MDX, the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)
GlobeNewswire - Fri Mar 07, 2:57AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX) to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that the US. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MDX. This step will allow for the initiation of US clinical trials.
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference
GlobeNewswire - Mon Feb 24, 7:08AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine extended-release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will give a presentation entitled, "The Use of Biomarkers in Fragile X and Autism Clinical Trials," at Autism Speaks' Autism Investment Conference, being held at the Bently Reserve Banking Hall in San Francisco on March 4-5, 2014. The Alcobra presentation is on Tuesday, March 4, during the "Medicines and Therapeutic Devices" session.
Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer
GlobeNewswire - Wed Feb 19, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, Metadoxine Extended Release (MDX; MG01CI), to treat cognitive dysfunction, announced today that it has appointed Dr. Tomer Berkovitz as Chief Financial Officer, effective May 1, 2014. Dr. Berkovitz will report to Dr. Yaron Daniely, President and Chief Executive Officer, and will be responsible for all Corporate Finance and Accounting activities for Alcobra.
Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update
GlobeNewswire - Thu Feb 13, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced its financial results for the quarter and year-ended December 31, 2013.
Alcobra Ltd submits IND to US FDA for Phase III development programme of MG01CI in adults with ADHD
M2 - Mon Feb 10, 6:55AM CST
Biopharmaceutical company Alcobra Ltd (NasdaqCM:ADHD) said on Friday that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI.
Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD
GlobeNewswire - Fri Feb 07, 12:59PM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI. The study is entitled "A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)."